Results of laboratory analyses at follow-up of patients who had sarcoidosis in childhood
| Variable | Subjects n | Median (range) | Reference interval | Abnormal n |
| Plasma total calcium mmol·L−1 | 35 | 2.52 (2.21–2.73) | 2.20–2.60 | 3# |
| Plasma ionised calcium mmol·L−1 | 32 | 1.25 (1.19–1.41) | 1.17–1.34 | 1¶ |
| Plasma IgG μmol·L−1 | 33 | 73 (43–95) | 41–99 | |
| Plasma IgA μmol·L−1 | 33 | 12.4 (4.0–23.1) | 4.4–22.8 | 2+ |
| Plasma IgM μmol·L−1 | 33 | 0.93 (0.29–1.92) | 0.41–2.19 | 2§ |
| Plasma IgE kIU·L−1 | 29 | 12 (2–412) | 0–100 | 2ƒ |
| SACE U·L−1 | 28 | 48 (25–130) | 30–115 | 1## |
| Serum soluble interleukin-2 receptor U·L−1 | 28 | 469 (317–1660) | 223–710 | 4¶¶ |
Ig: immunoglobulin; SACE: serum angiotensin-converting enzyme. #: one female with hypercalcaemia at diagnosis also had high ionised calcium at follow-up and was otherwise healthy, one female and one male without hypercalcaemia at diagnosis had normal ionised calcium at follow-up and were healthy; ¶: one female with hypercalcaemia at diagnosis was healthy at follow-up; +: one male with high IgA and healthy, one male with low IgA (patient 8) and healthy; §: one male with low IgM (patient 8) and healthy, one male with low IgM (patient 1) with steroid-treated chronic active pulmonary sarcoidosis; ƒ: one female with sarcoid diabetes insipidus and no allergy (patient 5), one female with chronic active stage III pulmonary sarcoidosis and no allergy (patient 6); ##: one female with chronic active stage III pulmonary sarcoidosis (patient 6); ¶¶: one female with serum soluble interleukin-2 receptor (S-sIL-2R) 876 U·L−1, SACE 113 U·L−1, chronic active stage I pulmonary sarcoidosis and diabetes insipidus and not on steroids (patient 5), one female with S-sIL-2R 1112 U·L−1, SACE 32 U·L−1, chronic active stage IV pulmonary sarcoidosis and intestinal sarcoidosis and was not on steroids, one female (patient 6) with S-sIL-2R 1280 U·L−1, SACE 130 U·L−1 with chronic active stage III pulmonary sarcoidosis and nephrocalcinosis and not on steroids, one male (patient 1) with S-sIL-2R 1680 U·L−1, SACE 85 U·L−1 with chronic active stage I pulmonary sarcoidosis and on steroids.